161 related articles for article (PubMed ID: 8879681)
1. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.
Rella C; Coviello M; Giotta F; Maiello E; Colavito P; Colangelo D; Quaranta M; Colucci G; Schittulli F
Breast Cancer Res Treat; 1996; 40(2):151-9. PubMed ID: 8879681
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis].
Oberhoff C; Winkler UH; Tauchert AM; Schindler AE
Zentralbl Gynakol; 1997; 119(5):211-7. PubMed ID: 9281254
[TBL] [Abstract][Full Text] [Related]
3. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant CMF-chemotherapy and haemostasis. Effect of "classical" and "modified" adjuvant CMF-chemotherapy on blood coagulation fibrinolysis in patients with breast cancer.
Oberhoff C; Winkler UH; Hoffmann O; Schindler AE
Eur J Gynaecol Oncol; 2000; 21(2):147-52. PubMed ID: 10843473
[TBL] [Abstract][Full Text] [Related]
5. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
6. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
von Tempelhoff GF; Dietrich M; Hommel G; Heilmann L
J Clin Oncol; 1996 Sep; 14(9):2560-8. PubMed ID: 8823336
[TBL] [Abstract][Full Text] [Related]
7. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.
;
Jpn J Cancer Res; 1993 Apr; 84(4):455-61. PubMed ID: 8514613
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
9. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
10. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of adjuvant chemotherapy for breast cancer patients.
Imoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):310-5. PubMed ID: 9390207
[TBL] [Abstract][Full Text] [Related]
12. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
Garcia-Avello A; Garcia-Frade LJ; Gandarias C; Ocaña J; Cancelas JA; Lasso M
Thromb Res; 1994 Jan; 73(2):109-15. PubMed ID: 8171409
[TBL] [Abstract][Full Text] [Related]
13. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.
Demirkan B; Ozcan MA; Glu AA; Yüksel F; Undar B; Alakavuklar M
Clin Appl Thromb Hemost; 2006 Jan; 12(1):9-14. PubMed ID: 16444429
[TBL] [Abstract][Full Text] [Related]
14. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
Winkler UH; Schindler AE; Endrikat J; Düsterberg B
Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis.
Oberhoff C; Szymeczek J; Hoffmann O; Winkler UH; Kaiser S; Schindler AE
Breast Cancer Res Treat; 1998 Jul; 50(1):73-81. PubMed ID: 9802622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
